7MM treatment-resistant hypertension market to grow 5% annually until 2034

Better diagnostic practices and combination therapy developments drive the sector.

The treatment-resistant hypertension (TRH) market across the seven major markets (7MM) is expected to expand at a compound annual growth rate of 5% from 2020 to 2034, according to a DelveInsight report.

The sector’s growth is attributed to the rising prevalence of uncontrolled hypertension and associated cardiovascular risks.

Moreover, better diagnostic practices, developments in combination therapies, and device-based interventions are driving market expansion.

“Advances in pharmaceuticals and procedures, along with innovations in pharmacogenomics, precision medicine, and digital health platforms, are expanding the landscape of treatment options for TRH,” the report said.

7MM = US, France, Germany, Italy, Spain, UK, and Japan